Effect of MAFLD on albuminuria and the interaction between MAFLD and diabetes on albuminuria
Abstract Objective To investigate the effects of metabolic associated fatty liver disease (MAFLD) on chronic kidney disease (CKD) and abnormal albuminuria and the interaction between MAFLD and diabetes on abnormal albuminuria. Methods Data of participants in the American 2017–2018 National Health an...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-02-01
|
| Series: | Journal of Diabetes |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1753-0407.13501 |
| _version_ | 1797294326945939456 |
|---|---|
| author | Yufang Liu Sanbao Chai Xiaomei Zhang |
| author_facet | Yufang Liu Sanbao Chai Xiaomei Zhang |
| author_sort | Yufang Liu |
| collection | DOAJ |
| description | Abstract Objective To investigate the effects of metabolic associated fatty liver disease (MAFLD) on chronic kidney disease (CKD) and abnormal albuminuria and the interaction between MAFLD and diabetes on abnormal albuminuria. Methods Data of participants in the American 2017–2018 National Health and Nutrition Examination Survey were analyzed. Hepatic steatosis was defined as median controlled attenuation parameter ≥248 dB/m, which was measured by ultrasound transient elastography. MAFLD was defined by evidence of hepatic steatosis on ultrasound in addition to any metabolic dysregulation. Hepatic fibrosis was detected by FibroScan and quantified by parameter of stiffness (E). Hepatic fibrosis was defined as E ≥ 9.7 kPa. As component of CKD, reduced estimated glomerular filtration rate (eGFR) was defined as<60 mL/min/1.73 m2 and abnormal albuminuria was defined as urinary albumin‐to‐creatinine ratio ≥ 30 mg/g. Results Data pertaining to 5119 participants were included in the analysis, with 40.6% hepatic normal, 52.1% MAFLD, and 7.2% hepatic fibrosis. Multivariable regression analyses showed that for abnormal albuminuria, the odds ratio (OR) was 0.82 (0.65–1.04) for MAFLD group and 1.73 (1.14.–,2.63) for hepatic fibrosis group, both taking the hepatic healthy group as reference. As for reduced eGFR, the OR was 0.68 (0.51–0.92) for MAFLD group and 0.93 (0.56–1.53) for hepatic fibrosis group. Diabetes was significantly related to greater risk of abnormal albuminuria (3.04 [2.70–3.42]) and reduced eGFR (1.53 [1.33–1.77]). With regard to the prevalence of abnormal albuminuria, the OR was 1.64 (1.03–2.60) for those with hepatic fibrosis only, 3.30 (2.80–3.89) for those with diabetes only, and 5.05 (3.30–7.72) for those with both two conditions. But there were neither additive interaction (relative excess risk due to interaction 0.56 [−1.41–.53], p = .577) nor multiplicative interaction (OR 0.81 [0.45–1.47], p = .492) between hepatic fibrosis and diabetes on the prevalence of abnormal albuminuria. Conclusion MAFLD with hepatic fibrosis is an independent risk factor for abnormal albuminuria, but it does not have interaction with diabetes on abnormal albuminuria. |
| first_indexed | 2024-03-07T21:29:36Z |
| format | Article |
| id | doaj.art-45a7f61a782746248dca88bb9cb01c83 |
| institution | Directory Open Access Journal |
| issn | 1753-0393 1753-0407 |
| language | English |
| last_indexed | 2024-03-07T21:29:36Z |
| publishDate | 2024-02-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes |
| spelling | doaj.art-45a7f61a782746248dca88bb9cb01c832024-02-27T01:30:32ZengWileyJournal of Diabetes1753-03931753-04072024-02-01162n/an/a10.1111/1753-0407.13501Effect of MAFLD on albuminuria and the interaction between MAFLD and diabetes on albuminuriaYufang Liu0Sanbao Chai1Xiaomei Zhang2Department of Endocrinology Peking University International Hospital Beijing ChinaDepartment of Endocrinology Peking University International Hospital Beijing ChinaDepartment of Endocrinology Peking University International Hospital Beijing ChinaAbstract Objective To investigate the effects of metabolic associated fatty liver disease (MAFLD) on chronic kidney disease (CKD) and abnormal albuminuria and the interaction between MAFLD and diabetes on abnormal albuminuria. Methods Data of participants in the American 2017–2018 National Health and Nutrition Examination Survey were analyzed. Hepatic steatosis was defined as median controlled attenuation parameter ≥248 dB/m, which was measured by ultrasound transient elastography. MAFLD was defined by evidence of hepatic steatosis on ultrasound in addition to any metabolic dysregulation. Hepatic fibrosis was detected by FibroScan and quantified by parameter of stiffness (E). Hepatic fibrosis was defined as E ≥ 9.7 kPa. As component of CKD, reduced estimated glomerular filtration rate (eGFR) was defined as<60 mL/min/1.73 m2 and abnormal albuminuria was defined as urinary albumin‐to‐creatinine ratio ≥ 30 mg/g. Results Data pertaining to 5119 participants were included in the analysis, with 40.6% hepatic normal, 52.1% MAFLD, and 7.2% hepatic fibrosis. Multivariable regression analyses showed that for abnormal albuminuria, the odds ratio (OR) was 0.82 (0.65–1.04) for MAFLD group and 1.73 (1.14.–,2.63) for hepatic fibrosis group, both taking the hepatic healthy group as reference. As for reduced eGFR, the OR was 0.68 (0.51–0.92) for MAFLD group and 0.93 (0.56–1.53) for hepatic fibrosis group. Diabetes was significantly related to greater risk of abnormal albuminuria (3.04 [2.70–3.42]) and reduced eGFR (1.53 [1.33–1.77]). With regard to the prevalence of abnormal albuminuria, the OR was 1.64 (1.03–2.60) for those with hepatic fibrosis only, 3.30 (2.80–3.89) for those with diabetes only, and 5.05 (3.30–7.72) for those with both two conditions. But there were neither additive interaction (relative excess risk due to interaction 0.56 [−1.41–.53], p = .577) nor multiplicative interaction (OR 0.81 [0.45–1.47], p = .492) between hepatic fibrosis and diabetes on the prevalence of abnormal albuminuria. Conclusion MAFLD with hepatic fibrosis is an independent risk factor for abnormal albuminuria, but it does not have interaction with diabetes on abnormal albuminuria.https://doi.org/10.1111/1753-0407.13501abnormal albuminuriadiabeteshepatic fibrosisMAFLDreduced eGFR |
| spellingShingle | Yufang Liu Sanbao Chai Xiaomei Zhang Effect of MAFLD on albuminuria and the interaction between MAFLD and diabetes on albuminuria Journal of Diabetes abnormal albuminuria diabetes hepatic fibrosis MAFLD reduced eGFR |
| title | Effect of MAFLD on albuminuria and the interaction between MAFLD and diabetes on albuminuria |
| title_full | Effect of MAFLD on albuminuria and the interaction between MAFLD and diabetes on albuminuria |
| title_fullStr | Effect of MAFLD on albuminuria and the interaction between MAFLD and diabetes on albuminuria |
| title_full_unstemmed | Effect of MAFLD on albuminuria and the interaction between MAFLD and diabetes on albuminuria |
| title_short | Effect of MAFLD on albuminuria and the interaction between MAFLD and diabetes on albuminuria |
| title_sort | effect of mafld on albuminuria and the interaction between mafld and diabetes on albuminuria |
| topic | abnormal albuminuria diabetes hepatic fibrosis MAFLD reduced eGFR |
| url | https://doi.org/10.1111/1753-0407.13501 |
| work_keys_str_mv | AT yufangliu effectofmafldonalbuminuriaandtheinteractionbetweenmafldanddiabetesonalbuminuria AT sanbaochai effectofmafldonalbuminuriaandtheinteractionbetweenmafldanddiabetesonalbuminuria AT xiaomeizhang effectofmafldonalbuminuriaandtheinteractionbetweenmafldanddiabetesonalbuminuria |